Artivion (NYSE:AORT) Stock Rating Upgraded by LADENBURG THALM/SH SH

Artivion (NYSE:AORT) was upgraded by research analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating in a research note issued on Friday, Marketbeat reports. The brokerage presently has a $42.00 price objective on the stock. LADENBURG THALM/SH SH’s price objective would indicate a potential upside of 11.61% from the company’s previous close.

A number of other brokerages have also weighed in on AORT. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price target on shares of Artivion in a research note on Tuesday, April 7th. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research note on Thursday, March 5th. Finally, Canaccord Genuity Group cut their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.00.

Artivion Trading Up 3.1%

Shares of NYSE:AORT opened at $37.63 on Friday. The company has a 50 day moving average of $37.15 and a 200-day moving average of $41.70. The firm has a market cap of $1.83 billion, a P/E ratio of 188.16 and a beta of 1.63. Artivion has a twelve month low of $22.22 and a twelve month high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, analysts anticipate that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In related news, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. This represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Lance A. Berry sold 6,316 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $238,618.48. Following the sale, the executive vice president directly owned 210,827 shares of the company’s stock, valued at approximately $7,965,044.06. This represents a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 133,043 shares of company stock valued at $4,977,158. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of large investors have recently made changes to their positions in AORT. Royal Bank of Canada raised its holdings in shares of Artivion by 107.0% during the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after acquiring an additional 20,010 shares during the period. AQR Capital Management LLC raised its holdings in shares of Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after acquiring an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after acquiring an additional 1,032 shares during the period. Creative Planning raised its holdings in shares of Artivion by 5.6% during the second quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after acquiring an additional 753 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after acquiring an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.